Literature DB >> 14585933

Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality.

Michael H Woo1, Carmen Losasso, Hong Guo, Luca Pattarello, Piero Benedetti, Mary-Ann Bjornsti.   

Abstract

Eukaryotic DNA topoisomerase I (Top1) is a monomeric protein clamp that functions in DNA replication, transcription, and recombination. Opposable "lip" domains form a salt bridge to complete Top1 protein clamping of duplex DNA. Changes in DNA topology are catalyzed by the formation of a transient phosphotyrosyl linkage between the active-site Tyr-723 and a single DNA strand. Substantial protein domain movements are required for DNA binding, whereas the tight packing of DNA within the covalent Top1-DNA complex necessitates some DNA distortion to allow rotation. To investigate the effects of Top1-clamp closure on enzyme catalysis, molecular modeling was used to design a disulfide bond between residues Gly-365 and Ser-534, to crosslink protein loops more proximal to the active-site tyrosine than the protein loops held by the Lys-369-Glu-497 salt bridge. In reducing environments, Top1-Clamp was catalytically active. However, contrary to crosslinking the salt-bridge loops [Carey, J. F., Schultz, S. J., Sission, L., Fazzio, T. G. & Champoux, J. J. (2003) Proc. Natl. Acad. Sci. USA 100, 5640-5645], crosslinking the active-site proximal loops inhibited DNA rotation. Apparently, subtle alterations in Top1 clamp flexibility impact enzyme catalysis in vitro. Yet, the catalytically active Top1-Clamp was cytotoxic, even in the reducing environment of yeast cells. Remarkably, a shift in redox potential in glr1Delta cells converted the catalytically inactive Top1Y723F mutant clamp into a cellular toxin, which failed to induce an S-phase terminal phenotype. This cytotoxic mechanism is distinct from that of camptothecin chemotherapeutics, which stabilize covalent Top1-DNA complexes, and it suggests that the development of novel therapeutics that promote Top1-clamp closure is possible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585933      PMCID: PMC283496          DOI: 10.1073/pnas.2235886100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Enzymes that push DNA around.

Authors:  J L Keck; J M Berger
Journal:  Nat Struct Biol       Date:  1999-10

Review 2.  Clinical use of topoisomerase I inhibitors in anticancer treatment.

Authors:  C Rodriguez-Galindo; K Radomski; C F Stewart; W Furman; V M Santana; P J Houghton
Journal:  Med Pediatr Oncol       Date:  2000-10

3.  Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.

Authors:  P Fiorani; J F Amatruda; A Silvestri; R H Butler; M A Bjornsti; P Benedetti
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

4.  Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures.

Authors:  M R Redinbo; L Stewart; J J Champoux; W G Hol
Journal:  J Mol Biol       Date:  1999-09-24       Impact factor: 5.469

Review 5.  Mechanism of action of camptothecin.

Authors:  L F Liu; S D Desai; T K Li; Y Mao; M Sun; S P Sim
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 6.  Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors.

Authors:  K W Kohn; Y Pommier
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

7.  Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I.

Authors:  C Hann; D L Evans; J Fertala; P Benedetti; M A Bjornsti; D J Hall
Journal:  J Biol Chem       Date:  1998-04-03       Impact factor: 5.157

8.  Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases.

Authors:  C Cheng; P Kussie; N Pavletich; S Shuman
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

Review 9.  Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme.

Authors:  D A Burden; N Osheroff
Journal:  Biochim Biophys Acta       Date:  1998-10-01

10.  Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA.

Authors:  C L Hann; A L Carlberg; M A Bjornsti
Journal:  J Biol Chem       Date:  1998-11-20       Impact factor: 5.157

View more
  19 in total

1.  Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics.

Authors:  G Chillemi; M Redinbo; A Bruselles; A Desideri
Journal:  Biophys J       Date:  2004-09-03       Impact factor: 4.033

2.  Free energy calculations reveal rotating-ratchet mechanism for DNA supercoil relaxation by topoisomerase IB and its inhibition.

Authors:  Jeff Wereszczynski; Ioan Andricioaei
Journal:  Biophys J       Date:  2010-08-04       Impact factor: 4.033

Review 3.  Cellular strategies for regulating DNA supercoiling: a single-molecule perspective.

Authors:  Daniel A Koster; Aurélien Crut; Stewart Shuman; Mary-Ann Bjornsti; Nynke H Dekker
Journal:  Cell       Date:  2010-08-20       Impact factor: 41.582

Review 4.  Human DNA topoisomerase I: relaxation, roles, and damage control.

Authors:  John B Leppard; James J Champoux
Journal:  Chromosoma       Date:  2005-04-14       Impact factor: 4.316

Review 5.  Repair of topoisomerase I-mediated DNA damage.

Authors:  Yves Pommier; Juana M Barcelo; V Ashutosh Rao; Olivier Sordet; Andrew G Jobson; Laurent Thibaut; Ze-Hong Miao; Jennifer A Seiler; Hongliang Zhang; Christophe Marchand; Keli Agama; John L Nitiss; Christophe Redon
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

6.  A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.

Authors:  Christophe Marchand; Smitha Antony; Kurt W Kohn; Mark Cushman; Alexandra Ioanoviciu; Bart L Staker; Alex B Burgin; Lance Stewart; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

7.  Analysis of human immunodeficiency virus type 1 Gag dimerization-induced assembly.

Authors:  Ayna Alfadhli; Tenzin Choesang Dhenub; Amelia Still; Eric Barklis
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1.

Authors:  Lorenzo Botta; Silvia Filippi; Claudio Zippilli; Silvia Cesarini; Bruno Mattia Bizzarri; Angela Cirigliano; Teresa Rinaldi; Alessandro Paiardini; Diego Fiorucci; Raffaele Saladino; Rodolfo Negri; Pietro Benedetti
Journal:  ACS Med Chem Lett       Date:  2020-04-10       Impact factor: 4.345

9.  DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.

Authors:  Christine M Wright; Marié van der Merwe; Amanda H DeBrot; Mary-Ann Bjornsti
Journal:  J Biol Chem       Date:  2015-03-20       Impact factor: 5.157

10.  Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.

Authors:  Komaraiah Palle; Luca Pattarello; Marié van der Merwe; Carmen Losasso; Piero Benedetti; Mary-Ann Bjornsti
Journal:  J Biol Chem       Date:  2008-08-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.